Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Fuji
Teva
Merck
Novartis
Baxter
Accenture
Argus Health
McKesson

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020923

« Back to Dashboard

NDA 020923 describes OPTIRAY 350, which is a drug marketed by Liebel-flarsheim and is included in two NDAs. It is available from one supplier. Additional details are available on the OPTIRAY 350 profile page.

The generic ingredient in OPTIRAY 350 is ioversol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.
Summary for 020923
Tradename:OPTIRAY 350
Applicant:Liebel-flarsheim
Ingredient:ioversol
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020923
Mechanism of ActionX-Ray Contrast Activity
Suppliers and Packaging for NDA: 020923
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923 NDA Liebel-Flarsheim Company LLC 0019-1323 0019-1323-21 12 BOTTLE, GLASS in 1 CARTON (0019-1323-21) > 200 mL in 1 BOTTLE, GLASS
OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923 NDA Liebel-Flarsheim Company LLC 0019-1323 0019-1323-81 20 SYRINGE, PLASTIC in 1 CARTON (0019-1323-81) > 125 mL in 1 SYRINGE, PLASTIC

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength51%
Approval Date:May 28, 1998TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength68%
Approval Date:May 29, 1998TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength74%
Approval Date:May 28, 1998TE:RLD:Yes

Expired US Patents for NDA 020923

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923-001 May 28, 1998 ➤ Subscribe ➤ Subscribe
Liebel-flarsheim OPTIRAY 320 ioversol INJECTABLE;INJECTION 020923-002 May 29, 1998 ➤ Subscribe ➤ Subscribe
Liebel-flarsheim OPTIRAY 350 ioversol INJECTABLE;INJECTION 020923-003 May 28, 1998 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Farmers Insurance
Citi
Novartis
Baxter
US Army
Julphar
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot